人工智慧輔助診斷軟體與糖尿病視網膜病變篩檢

AI-Assisted Diagnostic Tools and Diabetic Retinopathy Screening

糖尿病視網膜病變是糖尿病常見且嚴重的併發症，若未及時診斷與治療，可能導致不可逆的視力喪失。隨蓍糖尿病患者不斷增加，早期篩檢與治療對預防失明至關重要。然而，傳統眼底檢查受限於醫療資源與人力分配不均，特別在偏鄉地區更難普及。近年來，人工智慧技術革新了眼底影像分析，自動偵測病變徵象，其診斷準確度可媲美眼科醫師。台灣導入VeriSee DR等AI系統後，顯著改善了篩檢流程，提升了轉診效率與早期診斷率。此外，生成式AI如ChatGPT在臨床決策輔助、病歷摘要與醫病溝通方面，提供更高效的診療輔助。儘管前景樂觀，仍需克服影像品質、模型適應性與電子病歷整合等挑戰，並強化法規與倫理規範以確保AI應用的安全性。隨著技術發展，AI輔助篩檢將提升糖尿病照護品質。

Diabetic retinopathy is a common and serious complication of diabetes that, if not diagnosed and treated promptly, may lead to irreversible vision loss. With the increasing prevalence of diabetes, early screening and intervention are crucial for preventing blindness. However, traditional retinal examinations are constrained by the unequal distribution of medical resources and personnel, making them particularly challenging to implement in remote areas. In recent years, artificial intelligence has transformed fundus image analysis by automatically detecting pathological signs with diagnostic accuracy comparable to that of ophthalmologists. In Taiwan, the adoption of AI systems like VeriSee DR has significantly improved the screening process by improving referral efficiency and boosting early diagnosis rates. Furthermore, generative AI technologies such as ChatGPT provide more efficient support for clinical decision-making, summarization of electronic health records, and communication between doctors and patients. Despite the promising prospects, challenges such as image quality, model adaptability, and the integration of electronic health records still remain, necessitating stronger regulatory and ethical frameworks to ensure the safe application of AI. With ongoing technological advancements, AI-assisted screening is expected to further enhance the quality of diabetes care.